Institute of Experimental Medicine - Czech Academy of Sciences

What Institute of Experimental Medicine - Czech Academy of Sciences does

The Institute of Experimental Medicine of the Czech Academy of Sciences (IEM CAS; Ústav experimentální medicíny AV ČR, v.v.i.) is a public research institution founded in 1975 and headquartered in Prague 4, Czech Republic. It operates as a veřejná výzkumná instituce (v.v.i.) under the Czech Academy of Sciences and is organized around 12 specialized research departments and centres spanning cellular neurophysiology, developmental biology, reconstructive neuroscience, neurogenetics, tissue engineering, molecular biology of cancer, neuroregeneration, toxicology, molecular epidemiology, cell nucleus plasticity, genome biology, neurochemistry, functional organization of biomembranes, and auditory neuroscience. Its research focus is the discovery of diagnostic markers and treatments for serious age-associated diseases, including neurodegeneration, trauma, ischemia, musculoskeletal disorders, cancer, and degenerative vision and hearing loss.

The institute's service portfolio includes a Microscopy Service Centre, membership-based access to four research infrastructures (Euro-BioImaging, Czech-BioImaging, EATRIS, and NanoEnviCz), a portfolio of patents in neurodegeneration, cancer, and tissue engineering, a technology-transfer function for commercializing R&D outputs, and a public science-engagement programme. Research infrastructure includes co-location in the BIOCEV Research Centre (established 2015, 10-year anniversary in 2026) and an EU-co-financed International Mobility Programme. Output in 2025 included 79 publications and 31 active research projects across approximately 220 employees.

IEM CAS does not operate a commercial GTM model. Its activities are funded through institutional support from the Czech Academy of Sciences and competitive grants from Czech bodies (GA ČR, AZV ČR, MŠMT, Ministry of Health) and the European Union (Structural and Investment Funds, Operational Programme Research, Development and Education). Revenue is not publicly disclosed. Customer and partner relationships are primarily with Czech clinical hospitals (Thomayerova nemocnice, IKEM, VFN, FN Plzeň, FNKV), academic institutions (Masaryk University Brno, Charles University), and international research centres (DKFZ Heidelberg). Distribution of research outputs occurs through peer-reviewed publications, collaborative research projects, shared research infrastructure, seminars, and science-popularization events.

Name

Institute of Experimental Medicine - Czech Academy of Sciences

Legal name

Ústav experimentální medicíny Akademie věd České republiky, v.v.i.

Website

https://iem.cas.cz

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

101–250 employees

Short description

The Institute of Experimental Medicine of the Czech Academy of Sciences is a public biomedical research institute in Prague operating 12 specialized departments focused on diagnostics and treatments for age-related diseases including neurodegeneration, cancer, and sensory disorders, funded by Czech Academy of Sciences and EU grants.

Ownership category

akta.pro rank

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAIALAF

Translational Medicine & Biomarkers

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

• Biomedical research services
• Preclinical research
• Neuroscience research
• Molecular cancer biology
• Translational medicine research

Headquarters

HQ city

Prague 4

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Public Research Funding: Funded by Czech Academy of Sciences, European Union (Structural and Investment Funds, Operational Programme Research, Development and Education), Czech Science Foundation (GA ČR), Ministry of Health (AZV ČR), Ministry of Education (MŠMT), and other public research grants

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

The Institute of Experimental Medicine of the Czech Academy of Sciences is a public biomedical research institution conducting basic and translational research across 12 specialised departments covering cellular neurophysiology, developmental biology, reconstructive neuroscience, neurogenetics, tissue engineering, molecular biology of cancer, neuroregeneration, toxicology, molecular epidemiology, cell nucleus plasticity, genome biology, neurochemistry, functional biomembranes, and auditory neuroscience. It delivers research infrastructure services (including a Microscopy Service Centre), scientific publications, patents, and science popularisation programs, with a research focus on diagnostic markers and treatment of age-related diseases.

Product overview

The Institute of Experimental Medicine of the Czech Academy of Sciences (IEM CAS) is a biomedical research institution organized around 12 specialized research departments and centres, not a commercial product company. Its offerings consist of research services (including the Microscopy Service Centre), research infrastructure memberships (Euro-BioImaging, Czech-BioImaging, EATRIS, NanoEnviCz), intellectual property through patents, and public science engagement programs. The institute focuses on fundamental biomedical research aimed at diagnosis and treatment of age-related diseases including neurodegeneration, cancer, and sensory disorders.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 79 publications in 2025
• +2 more outcomes

Named customers7 records

Segments2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Euro-BioImagingcoreTechnology or IntegrationEuropean research infrastructure for biomedical imaging providing access to advanced imaging technologies and expertise
• Czech-BioImagingcoreTechnology or IntegrationCzech national research infrastructure for biomedical imaging enabling access to cutting-edge microscopy and imaging services
• EATRIScoreStrategic or Co-development PartnerEuropean research infrastructure for translational medicine facilitating collaboration in translational research
• BIOCEV Research CentrecoreStrategic or Co-development PartnerCollaborative research centre celebrating 10th anniversary in 2026, hosting multiple research teams from the institute
• Thomayerova nemocnice PrahacoreStrategic or Co-development PartnerClinical research collaboration in cancer and molecular epidemiology studies
• IKEM PrahacoreStrategic or Co-development PartnerClinical research collaboration in transplantology and related biomedical research
• Všeobecná fakultní nemocnice PrahacoreStrategic or Co-development PartnerClinical research collaboration in colorectal cancer and molecular biology
• Masarykova Univerzita BrnocoreStrategic or Co-development PartnerAcademic research collaboration in molecular biology and genetics
• DKFZ (German Cancer Research Center) HeidelbergcoreStrategic or Co-development PartnerInternational collaboration with leading cancer research center (prof. Hemminki, prof. Kumar, Dr. Canzian, Dr. Försti)
• European Inventor NetworkminorStrategic or Co-development PartnerScience popularisation collaboration supported by European Patent Office grant

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Regional players

• Institute of Molecular and Cell Biology (IMCB): A publicly funded biomedical research institute in Singapore with comparable mandate in molecular biology, cancer biology and regenerative medicine, though serving an Asia-Pacific geographic base.

Direct peers

• Institute of Molecular Genetics of the Czech Academy of Sciences: A sister institute within the Czech Academy of Sciences focused on molecular genetics, genome biology, and related biomedical research — directly comparable in mandate, funding model, and research scope to IEM CAS.
• Masaryk University Brno: Czech academic partner collaborating with IEM CAS in molecular biology and genetics; comparable in biomedical research scope and Czech public-research funding profile.
• CEITEC (Central European Institute of Technology): A Central European life sciences and advanced materials research centre based in Brno with comparable biomedical and translational research mandate under similar EU structural funding.
• Institute of Microbiology of the Czech Academy of Sciences: Another Academy of Sciences institute with overlapping biomedical and molecular biology research, sharing similar public funding structures and research infrastructure in the Czech Republic.
• Max Planck Institute for Biology of Ageing: A German research institute dedicated to ageing biology research — directly comparable in scientific focus (age-related disease) and public-nonprofit research model, though at a larger international scale.
• BIOCEV Research Centre: A joint biotechnology and biomedical research centre established in 2015, hosted by IEM CAS and partners, focused on molecular medicine, structural biology and biotechnology — directly comparable in research scope and Czech biomedical ecosystem role.

Broad incumbents

• Karolinska Institutet: A leading European medical university with broad biomedical and neuroscience research portfolio — comparable in research scope and publicly funded model, particularly in regenerative neuroscience and translational medicine.
• German Cancer Research Center (DKFZ): A leading European cancer research center with which IEM CAS maintains international collaboration (Prof. Hemminki, Kumar, Canzian, Försti); broader portfolio but directly comparable in cancer biology and molecular epidemiology research.
• Francis Crick Institute: A large biomedical research institute in London covering cancer, neuroscience, and infection biology — a comparable model of a multidisciplinary, publicly funded biomedical research organization at a much larger scale.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@iemcas
• Facebookfacebook.com/iemcas
• LinkedInlinkedin.com/company/iemcas
• Instagraminstagram.com/iemcas

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute of Experimental Medicine - Czech Academy of Sciences